Management and board changes at Oxford BioMedica
This article was originally published in Scrip
Executive Summary
Oxford BioMedica, a gene therapy company, has appointed Dr Alex Lewis director of corporate activities and strategy. He will step down from Oxford BioMedica's board to be replaced by Dr Paul Blake, who will become chairman of the company's remuneration committee, and Dr Andrew Heath who will also join the committee. Dr Lewis was appointed to Oxford BioMedica's board in April 2008 and was also director of transactions and due diligence at The Datamonitor Group until June 2009.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.